✦ LIBER ✦

9200 Phase II study of IPH1101 (with low dose of IL-2) in combination with rituximab re-treatment in patients with follicular lymphoma

✍ Scribed by Casasnovas, O.; Thieblemont, C.; Rossi, J.F.; Sicard, H.; Ingoure, S.; Audibert, F.; de Micheaux, S. Lafaye; Laurent, G.

Book ID: 123365069
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 50 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71891-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab in combination with fludarabin

Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma

✍ Stefano Sacchi; Samantha Pozzi; Raffaella Marcheselli; Massimo Federico; Alessan 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views

## Abstract ## BACKGROUND. The current study was conducted to asses the safety profile and clinical activity of rituximab in combination with fludarabine and cyclophosphamide in patients with recurrent follicular lymphoma (FL). ## METHODS. This study was a noncomparative, multicenter, phase II s

Phase 2 study of gemcitabine in combinat

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

✍ Yasuhiro Oki; Barbara Pro; Luis E. Fayad; Jorge Romaguera; Felipe Samaniego; Fre 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 2 views

## Abstract ## BACKGROUND. The management of recurrent or refractory Hodgkin lymphoma (HL) remains challenging. The objective of this phase 2 trial was to investigate the activity of gemcitabine in combination with rituximab in patients with recurring or refractory HL. ## METHODS. Patients were

Phase II study of a TLR-9 agonist (1018

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

✍ Jonathan W. Friedberg; Jennifer L. Kelly; Donna Neuberg; Derick R. Peterson; Jef 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB

Phase I/II study of treatment with matur

Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma

✍ P. Hersey; G. M. Halliday; M. L. Farrelly; C. DeSilva; M. Lett; S. W. Menzies 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 577 KB

Bortezomib, Bendamustine, and Rituximab

Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study

✍ Fowler, N.; Kahl, B. S.; Lee, P.; Matous, J. V.; Cashen, A. F.; Jacobs, S. A.; L 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 215 KB

Phase II study of bendamustine in combin

Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas

✍ Weidmann, E.; Neumann, A.; Fauth, F.; Atmaca, A.; Al-Batran, S. E.; Pauligk, C.; 📂 Article 📅 2011 🏛 Oxford University Press 🌐 English ⚖ 107 KB